Ammon News - SAN DIEGO- Stemedica Cell Technologies, Inc.,("Stemedica"), a world leader in stem cell research and manufacturing,announced the signing of an agreement today for its breakthrough stem cell and related technology.
The Jordanian Stem Cell Company has signed a five year
multi-million dollar agreement to purchase the technology from Stemedica's
wholly-owned subsidiary, Stemedica International, S.A. The signing ceremony
took place at the European Burns Association Congress in Lausanne,
Switzerland, accoridng to Reuters.

"This is an important day for Stemedica International," said Frank Schuller,
PhD, Stemedica International's Chairman. "This is a real testament to the
quality and integrity of our products and the experience, dedication and
professionalism of our team." The signing ceremony was attended by Mr. Sam
Alkhass, Chief Executive Officer of the Jordanian Stem Cell Company as well as
several representatives from Stemedica, including Dr. Schuller; Mark Tager,
MD, Executive for Stemedica's Dermatological Operations; Alex Kharazi, MD,
PhD, Stemedica's Vice President for Research and Manufacturing; and, Riccardo
Nisato, MBA, PhD, Director of Manufacturing and Business Development,
Stemedica International S.A.

"We are delighted to be working with Stemedica International," said Sam
Alkhass. "Jordan has an excellent reputation as a provider of innovative and
quality-driven medical treatment. It was fundamental to our company's future,
and Jordan's reputation, that we find the best possible partner within the
stem cell industry. We believe we have accomplished this objective by
securing a long-term exclusive relationship with Stemedica International."
Headquartered in Amman, The Jordanian Stem Cell Company is Chaired by His
Royal Highness, Prince Asem Bin Nayef.

"We would like to thank the Jordanian Stem Cell Company and its Chairman, His
Royal Highness, Prince Asem Bin Nayef for their vision and long-term
commitment in bringing adult stem technology to Jordan," said Roger J. Howe,
PhD, Chief Executive Officer for Stemedica International and Executive
Chairman for Stemedica. "Our working relationship will not only provide
significant medical advancements in treating the Citizens of Jordan, but will
allow the country to continue to build on its growing reputation as a, 'Center
of Medical Excellence' for the entire region. We have a quality partner in
The Jordanian Stem Cell Company and in the Country of Jordan and we look
forward to growing these relationships."

"Stemedica International will be providing our state-of-the-art stem cell
technology to the Jordanian Stem Cell Company and will actively support their
development and implementation of a Clinical Trial for burns," said Nikolai
Tankovich, MD, PhD, Stemedica's President and Chief Medical Officer and Vice
Chairman of Stemedica International. "We will work closely with the
leadership of the Jordanian Stem Cell Company to secure all necessary
governmental approvals for the Clinical Trial. The Trial is anticipated to
begin sometime in the first quarter of 2010."

Stemedica International S.A. is a Lausanne, Switzerland-based, wholly owned
subsidiary of Stemedica Cell Technologies, Inc. headquartered in San Diego,
California. Stemedica is a developer and manufacturer of clinical grade stem
cell products and is licensed by the State of California Food and Drug Branch.

About Stemedica Cell Technologies, Inc. Stemedica Cell Technologies Inc.
(www.stemedica.com) is a specialty biopharmaceutical company that is committed
to the development and manufacturing of best-in-class adult stem cells and
stem cell factors for use by approved research institutions and hospitals for
pre-clinical and human clinical trials. The company is currently developing
regulatory pathways for stroke and wound repair. Stemedica is headquartered in
San Diego, California.
Source: Reuters